45 results
6-K
EX-99.1
BYSI
BeyondSpring Inc
30 Dec 21
Current report (foreign)
12:30pm
-L1 inhibitors + radiation in patients with seven cancer types.
Third Quarter Financial Results
Research and development (“R&D”) expenses were $8.5 … months ended September 30,
Nine months ended September 30,
Note
Revenue
Operating expenses
Research and development
General and administrative
Loss
6-K
BYSI
BeyondSpring Inc
19 Mar 21
Current report (foreign)
4:05pm
March 15, 2021, to pursue an opportunity with a company focused on infectious diseases research and development. Dr. Tonra was instrumental in helping … the further research and development of Plinabulin in various anti-cancer indications, including the currently anticipated submission of the NDA
6-K
EX-99.1
p7wvdf58rt 887
16 Jun 21
BeyondSpring Announces First Quarter 2021 Financial Results and Provides a Corporate Update
8:36am
6-K
EX-99.1
5br0iywq36suusr9
26 Aug 21
BeyondSpring Announces Exclusive Commercialization and Co-development Agreement with Jiangsu Hengrui Pharmaceuticals for Plinabulin in Greater China
7:15am
6-K
EX-99.1
2bgsmj7 57z
21 Jun 18
BeyondSpring Reports Operational Updates and First Quarter 2018 Financial Results
6:07am
6-K
EX-99.1
i2u u21ub6
10 Sep 21
Current report (foreign)
8:30am
6-K
EX-99.1
vckqbfxfm
23 Oct 18
Beyondspring Provides Operational Update and Second-quarter 2018 Financial Results
9:15am
20-F
qrgxlfmjzhzd o5i
28 Apr 17
Annual report (foreign)
12:00am
6-K
h71dmdn8orezb
16 Nov 20
Current report (foreign)
7:22am
6-K
bq3ci4z6r9i 8mju
18 Mar 24
Current report (foreign)
8:30am
6-K
EX-99.1
c4t9y9whcq1 6g7
17 Nov 20
BeyondSpring Announces Third Quarter 2020 Financial Results and Provides Business Updates
8:06am
6-K
EX-99.1
egnn92xut4xlrea4t8vh
11 Jun 20
BeyondSpring Reports First-Quarter 2020 Financial Results and Operational Update
4:15pm
6-K
EX-99.1
btc0ogpzgnw 9ok9hk
3 Sep 20
BeyondSpring Provides Second-Quarter 2020 Financial Results and Business Updates
8:00am